Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Injection site pain

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    565 result(s) found for: Injection site pain. Displaying page 9 of 29.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2014-003822-42 Sponsor Protocol Number: B1971048 Start Date*: 2015-01-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years.
    Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018913-32 Sponsor Protocol Number: CACZ885H2357E1 Start Date*: 2010-08-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or...
    Medical condition: Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000285-38 Sponsor Protocol Number: APHP190020 Start Date*: 2019-08-21
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002830-19 Sponsor Protocol Number: RC31-18-0269 Start Date*: 2018-11-16
    Sponsor Name: Toulouse University Hospital
    Full Title: A randomized, double blind placebo-controlled multicenter study of the efficacy and safety of dupilumab in patients with moderate to severe hand eczema refractory to highly potent topical corticost...
    Medical condition: Chronic hand eczema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004501-14 Sponsor Protocol Number: EDC-3135 Start Date*: Information not available in EudraCT
    Sponsor Name:ZOLL, Inc.
    Full Title: COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED- CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION INP A TIE...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004018-15 Sponsor Protocol Number: V710-003 Start Date*: 2008-01-17
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult P...
    Medical condition: Staphylococcus aureus bacteremia Staphylococcus aureus mediastinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.0 10021881 - Infections and infestations 10066413 Staphylococcus aureus mediastinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) AT (Completed) FR (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004940-27 Sponsor Protocol Number: AIC316-03-II-01(Phase3) Start Date*: 2022-01-05
    Sponsor Name:AiCuris Anti-infective Cures GmbH
    Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ...
    Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004994-25 Sponsor Protocol Number: CSMS995A2101 Start Date*: 2008-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorecta...
    Medical condition: Irritable Bowel Syndrom
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024616-33 Sponsor Protocol Number: TRO40303CLEQ1491-1 Start Date*: 2011-08-04
    Sponsor Name:TROPHOS SA
    Full Title: Phase II, multicenter, randomized, double-blind, placebo controlled study to assess safety and efficacy of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary ...
    Medical condition: Treatment for cardiac reperfusion injury in patients undergoing PCI( Percutaneous coronary intervention) to treat an AMI (Acute Myocardial Infarction) and to assess safety as well as the ability of...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10000930 Acute myocardial infarction, unspecified site, initial episode of care LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004349-29 Sponsor Protocol Number: 01-10-2014 Start Date*: 2015-04-01
    Sponsor Name:Rigshospitalet
    Full Title: Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients
    Medical condition: The study will include participants with xerostomi (International Classification of Diseases-10: DQ 838A) and oropharyngeal cancer (DC 10).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10031103 Oropharyngeal cancer stage unspecified LLT
    17.1 100000004856 10048223 Xerostomia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001528-23 Sponsor Protocol Number: PB-102-F50 Start Date*: 2017-10-18
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 week...
    Medical condition: Fabry disease (α-galactosidase A deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) CZ (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003428-21 Sponsor Protocol Number: ABPOSTOPAPP Start Date*: 2017-03-14
    Sponsor Name:Erasmus Medical Centre
    Full Title: Non-inferiority multicentre randomized controlled trial comparing short versus standard course postoperative antibiotic treatment for complex acute appendicitis
    Medical condition: Complex appendicitis.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005529-11 Sponsor Protocol Number: UX023-CL303 Start Date*: 2016-02-01
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) FR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004055-20 Sponsor Protocol Number: VRV13 Start Date*: 2019-05-14
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004653-14 Sponsor Protocol Number: UoL000097 Start Date*: 2015-04-17
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE)
    Medical condition: Metastatic pancreatic carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004707-40 Sponsor Protocol Number: RAB40 Start Date*: 2019-02-25
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years.
    Medical condition: Rabies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001048-24 Sponsor Protocol Number: NN7769-4514 Start Date*: 2021-05-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.
    Medical condition: Haemophilia A Haemophilia A with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) AT (Completed) LV (Completed) LT (Completed) FR (Completed) NL (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005059-19 Sponsor Protocol Number: C0921062 Start Date*: 2021-03-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10076062 Meningococcal immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003321-42 Sponsor Protocol Number: NL58948.091.16 Start Date*: 2017-01-18
    Sponsor Name:Radboud University Medical Centre
    Full Title: Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study.
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003146-32 Sponsor Protocol Number: ASSIT Start Date*: 2013-03-04
    Sponsor Name:Hull and East Yorkshire Hospital Trust
    Full Title: A randomised control trial to determine whether a 5 day course of antibiotics is more clinically and cost effective than a 24 hour prophylactic course for the prevention of surgical site infection ...
    Medical condition: Incidence of Surgical Site infection following major lower limb amputation surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10036410 Postoperative wound infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 02:48:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA